Manuel Gomes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3079017/publications.pdf

Version: 2024-02-01

41 papers

1,590 citations

15 h-index 37 g-index

42 all docs 42 docs citations

42 times ranked 3642 citing authors

#	Article	IF	CITATIONS
1	A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials. Pharmacoeconomics, 2014, 32, 1157-1170.	3.3	417
2	Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 30 day outcomes from IMPROVE randomised trial. BMJ, The, 2014, 348, f7661-f7661.	6.0	367
3	Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials. Medical Decision Making, 2012, 32, 350-361.	2.4	119
4	EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. Value in Health, 2018, 21, 49-56.	0.3	71
5	Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial. Pharmacoeconomics, 2018, 36, 889-901.	3.3	69
6	Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials. Medical Decision Making, 2012, 32, 209-220.	2.4	46
7	METHODS FOR COVARIATE ADJUSTMENT IN COSTâ€EFFECTIVENESS ANALYSIS THAT USE CLUSTER RANDOMISED TRIALS. Health Economics (United Kingdom), 2012, 21, 1101-1118.	1.7	44
8	Addressing Missing Data in Patientâ€Reported Outcome Measures (PROMS): Implications for the Use of PROMS for Comparing Provider Performance. Health Economics (United Kingdom), 2016, 25, 515-528.	1.7	44
9	Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records. Lancet Diabetes and Endocrinology,the, 2021, 9, 681-694.	11.4	37
10	Missing data in trialâ€based costâ€effectiveness analysis: An incomplete journey. Health Economics (United Kingdom), 2018, 27, 1024-1040.	1.7	36
11	Multiple Imputation Methods for Handling Missing Data in Cost-effectiveness Analyses That Use Data from Hierarchical Studies. Medical Decision Making, 2013, 33, 1051-1063.	2.4	35
12	Development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes: Application to the IMPROVE trial. Clinical Trials, 2017, 14, 357-367.	1.6	33
13	Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice. Pharmacoeconomics, 2022, 40, 367-378.	3.3	26
14	Strategy of endovascular versus open repair for patients with clinical diagnosis of ruptured abdominal aortic aneurysm: the IMPROVE RCT. Health Technology Assessment, 2018, 22, 1-122.	2.8	22
15	Copula selection models for nonâ€Gaussian outcomes that are missing not at random. Statistics in Medicine, 2019, 38, 480-496.	1.6	20
16	Weight Change and the Onset of Cardiovascular Diseases: Emulating Trials Using Electronic Health Records. Epidemiology, 2021, 32, 744-755.	2.7	19
17	External Validation and Recalibration of Risk Prediction Models for Acute Traumatic Brain Injury among Critically Ill Adult Patients in the United Kingdom. Journal of Neurotrauma, 2015, 32, 1522-1537.	3.4	18
18	Handling Protest Responses in Contingent Valuation Surveys. Medical Decision Making, 2017, 37, 623-634.	2.4	18

#	Article	IF	Citations
19	Estimating the Effect of Reduced Attendance at Emergency Departments for Suspected Cardiac Conditions on Cardiac Mortality During the COVID-19 Pandemic. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007085.	2.2	18
20	Should English healthcare providers be penalised for failing to collect patient-reported outcome measures? A retrospective analysis. Journal of the Royal Society of Medicine, 2015, 108, 304-316.	2.0	15
21	Modelling the Health and Economic Impacts of Population-Wide Testing, Contact Tracing and Isolation (PTTI) Strategies for COVID-19 in the UK. SSRN Electronic Journal, 0, , .	0.4	15
22	A Bayesian framework for health economic evaluation in studies with missing data. Health Economics (United Kingdom), 2018, 27, 1670-1683.	1.7	14
23	Development, deployment and evaluation of digitally enabled, remote, supported rehabilitation for people with long COVID-19 (Living With COVID-19 Recovery): protocol for a mixed-methods study. BMJ Open, 2022, 12, e057408.	1.9	14
24	Referenceâ€based multiple imputation for missing data sensitivity analyses in trialâ€based costâ€effectiveness analysis. Health Economics (United Kingdom), 2020, 29, 171-184.	1.7	11
25	Cost-Effectiveness Analysis of 3-D Computerized Tomography Colonography Versus Optical Colonoscopy for Imaging Symptomatic Gastroenterology Patients. Applied Health Economics and Health Policy, 2013, 11, 107-117.	2.1	10
26	Cost-effectiveness of Memory Assessment Services for the diagnosis and early support of patients with dementia in England. Journal of Health Services Research and Policy, 2017, 22, 226-235.	1.7	10
27	Estimating treatment effects under untestable assumptions with nonignorable missing data. Statistics in Medicine, 2020, 39, 1658-1674.	1.6	7
28	The cost of diagnosis and early support in patients with cognitive decline. International Journal of Geriatric Psychiatry, 2018, 33, 5-13.	2.7	6
29	Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges. Pharmacoeconomics, 2022, , 1.	3.3	6
30	Handling incomplete correlated continuous and binary outcomes in metaâ€analysis of individual participant data. Statistics in Medicine, 2016, 35, 3676-3689.	1.6	4
31	Moving from two- to multi-way interactions among binary risk factors on the additive scale. Biostatistics and Epidemiology, 2020, 4, 282-293.	0.4	4
32	Understanding health and care expenditure by setting – who matters to whom?. Journal of Health Services Research and Policy, 2021, 26, 77-84.	1.7	4
33	Does a working day keep the doctor away? A critical review of the impact of unemployment and job insecurity on health and social care utilisation. European Journal of Health Economics, 2022, , 1.	2.8	3
34	Costâ€effectiveness analysis of English memory assessment services 2Âyears after first consultation for patients with dementia. International Journal of Geriatric Psychiatry, 2019, 34, 439-446.	2.7	2
35	Flexible Bayesian longitudinal models for costâ€effectiveness analyses with informative missing data. Health Economics (United Kingdom), 2021, 30, 3138-3158.	1.7	2
36	Comment on: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial. Pharmacoeconomics, 2018, 36, 1297-1297.	3.3	1

Manuel Gomes

#	Article	IF	CITATIONS
37	Copula Models for Addressing Sample Selection in the Evaluation of Public Health Programmes: An Application to the Leeds Let's Get Active Study. Applied Health Economics and Health Policy, 2021, 19, 305-312.	2.1	1
38	The Authors Respond. Epidemiology, 2022, 33, e4-e5.	2.7	1
39	Barriers and facilitators of use of analytics for strategic health and care decision-making: a qualitative study of senior health and care leaders' perspectives. BMJ Open, 2022, 12, e055504.	1.9	1
40	Rejoinder. Clinical Trials, 2017, 14, 370-371.	1.6	0
41	33â€Cost-effectiveness of ventricular tachycardia catheter ablation: limitations in the current trial evidence base. , 2019, , .		0